27 related articles for article (PubMed ID: 8320924)
1. Hemodialysis without systemic anticoagulation: a prospective randomized trial to evaluate 3 strategies in patients at risk of bleeding.
Guéry B; Alberti C; Servais A; Harrami E; Bererhi L; Zins B; Touam M; Joly D
PLoS One; 2014; 9(5):e97187. PubMed ID: 24825343
[TBL] [Abstract][Full Text] [Related]
2. High-flux versus low-flux membranes for end-stage kidney disease.
Palmer SC; Rabindranath KS; Craig JC; Roderick PJ; Locatelli F; Strippoli GF
Cochrane Database Syst Rev; 2012 Sep; 2012(9):CD005016. PubMed ID: 22972082
[TBL] [Abstract][Full Text] [Related]
3. Endogenous bradykinin contributes to increased plasminogen activator inhibitor 1 antigen following hemodialysis.
Marney AM; Ma J; Luther JM; Ikizler TA; Brown NJ
J Am Soc Nephrol; 2009 Oct; 20(10):2246-52. PubMed ID: 19628666
[TBL] [Abstract][Full Text] [Related]
4. Hyperfibrinolysis in alcoholic cirrhosis: relative plasminogen activator inhibitor type 1 deficiency.
Ferguson JW; Helmy A; Ludlam C; Webb DJ; Hayes PC; Newby DC
Thromb Res; 2008; 121(5):675-80. PubMed ID: 17870147
[TBL] [Abstract][Full Text] [Related]
5. [Tissue plasminogen activator antigen (t-PA Ag) and tissue plasminogen activator inhibitor (PAI-1) in the course of hemodialysis in patients with chronic renal failure].
Piatkowska M; Kotschy M; Nartowicz E; Rajewski W
Pol Merkur Lekarski; 1997 Jan; 2(9):205-7. PubMed ID: 10907030
[TBL] [Abstract][Full Text] [Related]
6. [Hypofibrinolysis after venous occlusion in patients treated with long-term hemodialysis].
Opatrný K; Vít L; Opatrná S; Sulková S; Bodláková B
Cas Lek Cesk; 1994 May; 133(11):346-9. PubMed ID: 8004664
[TBL] [Abstract][Full Text] [Related]
7. Fibrinolytic activity in peripheral atherosclerosis in the elderly.
van der Bom JG; Bots ML; Haverkate F; Meyer P; Hofman A; Grobbee DE; Kluft C
Thromb Haemost; 1999 Feb; 81(2):275-80. PubMed ID: 10064006
[TBL] [Abstract][Full Text] [Related]
8. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
[TBL] [Abstract][Full Text] [Related]
9. Fibrinolytic activity during hemodialysis: a biocompatibility-related phenomenon.
Martin-Malo A; Velasco F; Rojas R; Castillo D; Rodriguez M; Torres A; Aljama P
Kidney Int Suppl; 1993 Jun; 41():S213-6. PubMed ID: 8320924
[TBL] [Abstract][Full Text] [Related]
10. Fibrinolysis in chronic renal failure, dialysis and renal transplantation.
Opatrný K; Zemanová P; Opatrná S; Vít L
Ann Transplant; 2002; 7(1):34-43. PubMed ID: 12221902
[TBL] [Abstract][Full Text] [Related]
11. [Application of nanotechnology to hemodialysis membrane].
Uesaka M
Nihon Rinsho; 2006 Feb; 64(2):309-15. PubMed ID: 16454186
[TBL] [Abstract][Full Text] [Related]
12. New aspects of biocompatibility of hemodialysis membranes.
Wauters JP; Markert M
Adv Nephrol Necker Hosp; 1991; 20():275-80. PubMed ID: 2063716
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
